Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Primary cervical screening with high risk human papillomavirus testing: observational study.

Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, Smith J, Evans C, Giles T, Frew V, Tyler X, Sargent A, Parker J, Holbrook M, Hunt K, Tidbury P, Levine T, Smith D, Patnick J, Stubbs R, Moss S, Kitchener H.

BMJ. 2019 Feb 6;364:l240. doi: 10.1136/bmj.l240.

2.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

PMID:
29554468
3.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

4.

The contribution of a negative colorectal screening test result to symptom appraisal and help-seeking behaviour among patients subsequently diagnosed with an interval colorectal cancer.

Barnett KN, Weller D, Smith S, Steele RJ, Vedsted P, Orbell S, Moss SM, Melia JW, Patnick J, Campbell C.

Health Expect. 2018 Aug;21(4):764-773. doi: 10.1111/hex.12672. Epub 2018 Feb 19.

5.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

6.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

PMID:
29211316
7.

Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.

Cooper JA, Parsons N, Stinton C, Mathews C, Smith S, Halloran SP, Moss S, Taylor-Phillips S.

Br J Cancer. 2018 Jan;118(2):285-293. doi: 10.1038/bjc.2017.375. Epub 2017 Nov 2.

8.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

9.

Mammographic density and ageing: A collaborative pooled analysis of cross-sectional data from 22 countries worldwide.

Burton A, Maskarinec G, Perez-Gomez B, Vachon C, Miao H, Lajous M, López-Ridaura R, Rice M, Pereira A, Garmendia ML, Tamimi RM, Bertrand K, Kwong A, Ursin G, Lee E, Qureshi SA, Ma H, Vinnicombe S, Moss S, Allen S, Ndumia R, Vinayak S, Teo SH, Mariapun S, Fadzli F, Peplonska B, Bukowska A, Nagata C, Stone J, Hopper J, Giles G, Ozmen V, Aribal ME, Schüz J, Van Gils CH, Wanders JOP, Sirous R, Sirous M, Hipwell J, Kim J, Lee JW, Dickens C, Hartman M, Chia KS, Scott C, Chiarelli AM, Linton L, Pollan M, Flugelman AA, Salem D, Kamal R, Boyd N, Dos-Santos-Silva I, McCormack V.

PLoS Med. 2017 Jun 30;14(6):e1002335. doi: 10.1371/journal.pmed.1002335. eCollection 2017 Jun.

10.

Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials.

Raine R, Atkin W, von Wagner C, Duffy S, Kralj-Hans I, Hackshaw A, Counsell N, Moss S, McGregor L, Palmer C, Smith SG, Thomas M, Howe R, Vart G, Band R, Halloran SP, Snowball J, Stubbs N, Handley G, Logan R, Rainbow S, Obichere A, Smith S, Morris S, Solmi F, Wardle J.

Southampton (UK): NIHR Journals Library; 2017 Mar.

11.

Psychological Impact of Primary Screening (PIPS) for HPV: a protocol for a cross-sectional evaluation within the NHS cervical screening programme.

McBride E, Marlow L, Forster AS, Moss S, Myles J, Kitchener H, Patnick J, Waller J.

BMJ Open. 2016 Dec 23;6(12):e014356. doi: 10.1136/bmjopen-2016-014356.

12.

Mammographic density assessed on paired raw and processed digital images and on paired screen-film and digital images across three mammography systems.

Burton A, Byrnes G, Stone J, Tamimi RM, Heine J, Vachon C, Ozmen V, Pereira A, Garmendia ML, Scott C, Hipwell JH, Dickens C, Schüz J, Aribal ME, Bertrand K, Kwong A, Giles GG, Hopper J, Pérez Gómez B, Pollán M, Teo SH, Mariapun S, Taib NA, Lajous M, Lopez-Riduara R, Rice M, Romieu I, Flugelman AA, Ursin G, Qureshi S, Ma H, Lee E, Sirous R, Sirous M, Lee JW, Kim J, Salem D, Kamal R, Hartman M, Miao H, Chia KS, Nagata C, Vinayak S, Ndumia R, van Gils CH, Wanders JO, Peplonska B, Bukowska A, Allen S, Vinnicombe S, Moss S, Chiarelli AM, Linton L, Maskarinec G, Yaffe MJ, Boyd NF, Dos-Santos-Silva I, McCormack VA.

Breast Cancer Res. 2016 Dec 19;18(1):130.

13.

A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.

Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW.

Br J Cancer. 2016 Dec 6;115(12):1479-1486. doi: 10.1038/bjc.2016.365. Epub 2016 Nov 22.

14.

Impact of cause of death adjudication on the results of the European prostate cancer screening trial.

Walter SD, de Koning HJ, Hugosson J, Talala K, Roobol MJ, Carlsson S, Zappa M, Nelen V, Kwiatkowski M, Páez Á, Moss S, Auvinen A; ERSPC Cause of Death Committees.

Br J Cancer. 2017 Jan 3;116(1):141-148. doi: 10.1038/bjc.2016.378. Epub 2016 Nov 17.

15.

Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).

Bokhorst LP, Zappa M, Carlsson SV, Kwiatkowski M, Denis L, Paez A, Hugosson J, Moss S, Auvinen A, Roobol MJ.

BJU Int. 2016 Nov;118(5):677-680. doi: 10.1111/bju.13505. Epub 2016 May 20. No abstract available.

16.

Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.

Hakama M, Moss SM, Stenman UH, Roobol MJ, Zappa M, Carlsson S, Randazzo M, Nelen V, Hugosson J.

J Med Screen. 2017 Jun;24(2):98-103. doi: 10.1177/0969141316652174. Epub 2016 Aug 9.

17.

Understanding of a negative bowel screening result and potential impact on future symptom appraisal and help-seeking behaviour: a focus group study.

Barnett KN, Weller D, Smith S, Orbell S, Vedsted P, Steele RJC, Melia JW, Moss SM, Patnick J, Campbell C.

Health Expect. 2017 Aug;20(4):584-592. doi: 10.1111/hex.12484. Epub 2016 Jul 14.

18.

Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.

Moss S, Mathews C, Day TJ, Smith S, Seaman HE, Snowball J, Halloran SP.

Gut. 2017 Sep;66(9):1631-1644. doi: 10.1136/gutjnl-2015-310691. Epub 2016 Jun 7.

PMID:
27267903
19.

Assessing within-woman changes in mammographic density: a comparison of fully versus semi-automated area-based approaches.

Busana MC, De Stavola BL, Sovio U, Li J, Moss S, Humphreys K, dos-Santos-Silva I.

Cancer Causes Control. 2016 Apr;27(4):481-91. doi: 10.1007/s10552-016-0722-9. Epub 2016 Feb 4.

20.

Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.

Raine R, Duffy SW, Wardle J, Solmi F, Morris S, Howe R, Kralj-Hans I, Snowball J, Counsell N, Moss S, Hackshaw A, von Wagner C, Vart G, McGregor LM, Smith SG, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Atkin W.

Br J Cancer. 2016 Feb 2;114(3):321-6. doi: 10.1038/bjc.2015.413. Epub 2016 Jan 7.

21.

International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries.

McCormack VA, Burton A, dos-Santos-Silva I, Hipwell JH, Dickens C, Salem D, Kamal R, Hartman M, Lee CP, Chia KS, Ozmen V, Aribal ME, Flugelman AA, Lajous M, Lopez-Riduara R, Rice M, Romieu I, Ursin G, Qureshi S, Ma H, Lee E, van Gils CH, Wanders JO, Vinayak S, Ndumia R, Allen S, Vinnicombe S, Moss S, Won Lee J, Kim J, Pereira A, Garmendia ML, Sirous R, Sirous M, Peplonska B, Bukowska A, Tamimi RM, Bertrand K, Nagata C, Kwong A, Vachon C, Scott C, Perez-Gomez B, Pollan M, Maskarinec G, Giles G, Hopper J, Stone J, Rajaram N, Teo SH, Mariapun S, Yaffe MJ, Schüz J, Chiarelli AM, Linton L, Boyd NF.

Cancer Epidemiol. 2016 Feb;40:141-51. doi: 10.1016/j.canep.2015.11.015. Epub 2015 Dec 24.

22.

Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.

Wardle J, von Wagner C, Kralj-Hans I, Halloran SP, Smith SG, McGregor LM, Vart G, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Counsell N, Morris S, Duffy SW, Hackshaw A, Moss S, Atkin W, Raine R.

Lancet. 2016 Feb 20;387(10020):751-9. doi: 10.1016/S0140-6736(15)01154-X. Epub 2015 Dec 9.

23.

Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J.

Clin Cancer Res. 2016 Jan 1;22(1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. Epub 2015 Aug 19. Erratum in: Clin Cancer Res. 2016 Jul 15;22(14):3702.

24.

Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.

Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW.

Lancet Oncol. 2015 Sep;16(9):1123-1132. doi: 10.1016/S1470-2045(15)00128-X. Epub 2015 Jul 20. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

PMID:
26206144
25.

Corrigendum to "Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial" [Eur Urol 2013;64:703-9].

Bergdahl AG, Holmberg E, Moss S, Hugosson J.

Eur Urol. 2015 Aug;68(2):e46. doi: 10.1016/j.eururo.2015.01.021. Epub 2015 Feb 4. No abstract available.

PMID:
26149731
26.

Prostate cancer screening in Europe - Authors' reply.

Schröder F, Hugosson J, Carlsson S, Moss S, Roobol M, Auvinen A.

Lancet. 2015 Apr 18;385(9977):1507-8. doi: 10.1016/S0140-6736(15)60749-8. No abstract available.

PMID:
25933276
27.

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.

Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.

28.

Case-control Studies on the Effectiveness of Breast Cancer Screening: Insights from the UK Age Trial.

van der Waal D, Broeders MJ, Verbeek AL, Duffy SW, Moss SM.

Epidemiology. 2015 Jul;26(4):590-6. doi: 10.1097/EDE.0000000000000285.

PMID:
25767987
29.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators.

Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

30.

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA.

Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Erratum in: Eur Urol. 2015 Jun;67(6):e126.

31.

Colonoscopic factors associated with adenoma detection in a national colorectal cancer screening program.

Lee TJ, Rees CJ, Blanks RG, Moss SM, Nickerson C, Wright KC, James PW, McNally RJ, Patnick J, Rutter MD.

Endoscopy. 2014 Mar;46(3):203-11. doi: 10.1055/s-0033-1358831. Epub 2014 Jan 28.

32.

Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists.

Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, Humphrey PA, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S, Egevad L.

Histopathology. 2014 Aug;65(2):216-27. doi: 10.1111/his.12382. Epub 2014 Apr 3.

PMID:
24467262
33.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

34.

Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.

Massat NJ, Moss SM, Halloran SP, Duffy SW.

J Med Screen. 2013;20(3):125-48. doi: 10.1177/0969141313501292. Review.

PMID:
24197771
35.

Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, Roobol MJ.

Eur Urol. 2014 Feb;65(2):329-36. doi: 10.1016/j.eururo.2013.08.005. Epub 2013 Aug 11.

PMID:
23954085
36.

Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.

Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J.

Eur Urol. 2013 Nov;64(5):703-9. doi: 10.1016/j.eururo.2013.05.024. Epub 2013 May 17. Erratum in: Eur Urol. 2015 Aug;68(2):e46.

PMID:
23721957
37.

Pitfalls in Autier and Boniol's estimate of self-selection in case-control studies.

Broeders MJ, Moss SM.

Eur J Cancer Prev. 2014 Jan;23(1):69-70. doi: 10.1097/CEJ.0b013e328360f469. No abstract available.

PMID:
23532036
38.

Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.

van Leeuwen PJ, Kranse R, Hakulinen T, Hugosson J, Tammela TL, Ciatto S, Roobol MJ, Zappa M, de Koning HJ, Bangma CH, Moss SM, Auvinen A, Schröder FH.

J Med Screen. 2013 Mar;20(1):33-38. doi: 10.1258/jms.2013.012026.

PMID:
28075228
39.

Excess all-cause mortality in the evaluation of a screening trial to account for selective participation.

Kranse R, van Leeuwen PJ, Hakulinen T, Hugosson J, Tammela TL, Ciatto S, Roobol MJ, Zappa M, Aus G, Bangma CH, Moss SM, Auvinen A, Schröder FH.

J Med Screen. 2013 Mar;20(1):39-45. doi: 10.1177/0969141312474443. Epub 2013 May 13.

PMID:
23390204
40.

Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.

van Leeuwen PJ, Kranse R, Hakulinen T, Hugosson J, Tammela TL, Ciattoy S, Roobol MJ, Zappa M, de Koning HJ, Bangma CH, Moss SM, Auvinen A, Schröder FH.

J Med Screen. 2013 Mar;20(1):33-8.

PMID:
23390203
41.

Standardization of Gleason grading among 337 European pathologists.

Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Compérat E, Evans AJ, Griffiths D, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Moss S, Oliveira P, Vainer B, Varma M, Camparo P.

Histopathology. 2013 Jan;62(2):247-56. doi: 10.1111/his.12008.

PMID:
23240715
42.

Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom.

Gunsoy NB, Garcia-Closas M, Moss SM.

Breast Cancer Res. 2012 Nov 29;14(6):R152. doi: 10.1186/bcr3365.

43.

Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies.

Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E; Euroscreen Working Group.

J Med Screen. 2012;19 Suppl 1:33-41. Review.

PMID:
22972809
44.

The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies.

Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, Massat N, Duffy S, Lynge E, Paci E; EUROSCREEN Working Group.

J Med Screen. 2012;19 Suppl 1:14-25. Review.

PMID:
22972807
45.

Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study.

Legood R, Smith M, Lew JB, Walker R, Moss S, Kitchener H, Patnick J, Canfell K.

BMJ. 2012 Oct 31;345:e7086. doi: 10.1136/bmj.e7086.

46.

Quality-of-life effects of prostate-specific antigen screening.

Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ.

N Engl J Med. 2012 Aug 16;367(7):595-605. doi: 10.1056/NEJMoa1201637.

47.

Colonoscopy as a primary screening method?

Moss S.

J Med Screen. 2012 Jun;19(2):55-6. doi: 10.1258/jms.2012.012058. No abstract available.

PMID:
22753873
48.

Prostate-cancer mortality at 11 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators.

N Engl J Med. 2012 Mar 15;366(11):981-90. doi: 10.1056/NEJMoa1113135. Erratum in: N Engl J Med. 2012 May 31;366(22):2137.

49.

The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer.

Beral V, Alexander M, Duffy S, Ellis IO, Given-Wilson R, Holmberg L, Moss SM, Ramirez A, Reed MW, Rubin C, Whelehan P, Wilson R, Young KC.

J Med Screen. 2011;18(4):210-2. doi: 10.1258/jms.2011.011134. Review.

50.

Evaluation of the use of digital images for a national prostate core external quality assurance scheme.

Harnden P, Coleman D, Moss S, Kodikara S, Griffin NR, Melia J.

Histopathology. 2011 Oct;59(4):703-9. doi: 10.1111/j.1365-2559.2011.03987.x.

PMID:
22014051

Supplemental Content

Loading ...
Support Center